Biotech Values

[Summer2762]

I am extremely surprised by this. One co-primary end point doesn't reach statistical significance and the trial still ends early? Did J&J apply a little bit of pressure on DMC to get abiraterone out asap to hamper the MDV3100 trial or prevent MDV3100 messing abi data? Now, we wont even know the real OS advantage was. I knew that the choice of DMC makes a difference but I didnt expect this.